New cancer clinical trial: Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

Published on: February 28, 2018 at 12:00PM
Conditions:   Stomach Cancer;   Gastro Esophageal Junction Cancer
Interventions:   Drug: Atezolizumab;   Drug: Capecitabine;   Drug: Oxaliplatin;   Drug: Docetaxel
Sponsors:   The Netherlands Cancer Institute;   Hoffmann-La Roche
Not yet recruiting
http://ift.tt/2tdeZia